BioXcel Therapeutics (NASDAQ:BTAI – Free Report) had its price objective decreased by HC Wainwright from $7.00 to $5.00 in a report released on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.54) EPS.
Several other brokerages also recently commented on BTAI. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a research report on Friday, August 30th. UBS Group dropped their price target on BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th.
Get Our Latest Stock Report on BioXcel Therapeutics
BioXcel Therapeutics Stock Performance
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.55. The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period in the previous year, the business posted ($1.83) earnings per share. On average, analysts forecast that BioXcel Therapeutics will post -1.84 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in BTAI. Point72 Asia Singapore Pte. Ltd. bought a new position in BioXcel Therapeutics in the 2nd quarter worth approximately $39,000. Rosalind Advisors Inc. acquired a new stake in shares of BioXcel Therapeutics during the 2nd quarter worth approximately $51,000. XTX Topco Ltd grew its holdings in shares of BioXcel Therapeutics by 49.0% during the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after purchasing an additional 15,291 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of BioXcel Therapeutics during the 4th quarter worth approximately $176,000. Finally, Vanguard Group Inc. grew its holdings in shares of BioXcel Therapeutics by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock worth $3,100,000 after purchasing an additional 9,912 shares in the last quarter. 30.68% of the stock is owned by institutional investors.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Articles
- Five stocks we like better than BioXcel Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How is Compound Interest Calculated?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.